FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for ATTRv-PN

summarizeSummary

Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) in ATTRv-PN, allowing the company to resume patient enrollment and dosing.

check_boxKey Events

• Clinical Hold Lifted for MAGNITUDE-2 Trial

  The U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

• Trial Resumption and Enrollment Increase

  Intellia plans to resume patient enrollment and dosing for the MAGNITUDE-2 trial. The target enrollment for the trial has been increased from approximately 50 patients to approximately 60 patients.

• Study Modifications and Safety Measures

  The company has aligned with the FDA on certain study modifications and mitigation measures, including enhanced safety monitoring of liver laboratory tests, following a previous observation of Grade 4 liver transaminases and increased total bilirubin in a patient.

• Ongoing Engagement for MAGNITUDE Trial

  FDA engagement is still ongoing regarding the clinical hold on the IND for the MAGNITUDE Phase 3 clinical trial of nex-z for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), with an update expected once alignment is achieved.

auto_awesomeAnalysis

The FDA's decision to lift the clinical hold on the MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) is a significant positive development for Intellia Therapeutics. This allows the company to resume patient enrollment and dosing for a key pipeline asset targeting hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). While engagement with the FDA is ongoing for the related MAGNITUDE trial in ATTR-CM, the resolution for MAGNITUDE-2 removes a major regulatory hurdle and de-risks a portion of the nex-z program, potentially accelerating its path to market. The agreed-upon study modifications and enhanced safety monitoring demonstrate a clear path forward for this trial.